Pilot Study on Evaluating the Geroprotective Effect of Metformin

Sponsor
Xuanwu Hospital, Beijing
Study ID
NCT06459310
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Aging
  • Metformin

Eligibility Criteria

Sex
MALE
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Metformin Hydrochloride tablet — DRUG
    Extended release oral tablets, 1000 mg/day, single dose
  • Placebo — DRUG
    Oral tablets, 1000 mg/day, single dose

Study Details

The objective of this research is to assess the efficacy of oral metformin in mitigating the aging process in middle-aged and elderly males, to pinpoint sensitive indicators of human senescence, and to offer innovative frameworks and scientific insights for pharmaceutical interventions in aging.

Key Dates

Start date
Jun 30, 2024
Status verified
Mar 2025
Primary completion
Sep 30, 2026
Completion
Jul 31, 2028

Study Design

Enrollment
130 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Metformin hydrochloride
    1000 mg/day Metformin hydrochloride extended-release tablets
  • Placebo Comparator: Placebo group
    1000 mg/day placebo

Primary Outcome Measure

Composite the efficacy of metformin in intervening aging [ Time Frame: Baseline - 12 month ]

Central Contacts

Related Studies